Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment

Oncogene

Volumn 34, Issue 2, 2015, Pages 144-153

  Kwon, Y ^a,b   Smith, B D ^c   Zhou, Y ^d   Kaufman, M D ^c   Godwin, A K ^a,e  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b Ewha Womans University   (South Korea)

^c Deciphera Pharmaceuticals LLC   (United States)

^d FOX CHASE CANCER CENTER   (United States)

^e UNIVERSITY OF KANSAS CANCER CENTER   (United States)

Author keywords

c MET; DCC 2701; hepatocyte growth factor; human ovarian fibroblast; ovarian cancer

Indexed keywords

AMINOPYRIDINE DERIVATIVE; ANILIDE; DCC-2701; HGF PROTEIN, HUMAN; SCATTER FACTOR; SCATTER FACTOR RECEPTOR;

ANIMAL; ANTAGONISTS AND INHIBITORS; CELL COMMUNICATION; CELL MOTION; CELL PROLIFERATION; DISEASE COURSE; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; FEMALE; FIBROBLAST; HUMAN; METABOLISM; MOUSE; NUDE MOUSE; OVARIAN NEOPLASMS; PATHOLOGY; PHYSIOLOGY; RANDOMIZATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

AMINOPYRIDINES; ANILIDES; ANIMALS; CELL COMMUNICATION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; FIBROBLASTS; HEPATOCYTE GROWTH FACTOR; HUMANS; MICE; MICE, NUDE; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MET; RANDOM ALLOCATION; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84962440758     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.539     Document Type: Article

References (41)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Ozols RF, Bookman MA, Connolly DC, Daly MB, Godwin AK, Schilder RJ et al. Focus on epithelial ovarian cancer. Cancer Cell 2004; 5: 19-24.
3. Bhowmick NA, Moses HL. Tumor-stroma interactions. Curr Opin Genet Dev 2005; 15: 97-101.
4. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001; 411: 375-379.
5. Beacham DA, Cukierman E. Stromagenesis: the changing face of fibroblastic microenvironments during tumor progression. Semin Cancer Biol 2005; 15: 329-341.
6. Hynes RO. The extracellular matrix: not just pretty fibrils. Science 2009; 326: 1216-1219.
7. Matsumoto K, Nakamura T. Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions. Int J Cancer 2006; 119: 477-483.
8. Sierra JR, Tsao MS. c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol 2011; 3(1 Suppl): S21-S35.
9. Corps AN, Sowter HM, Smith SK. Hepatocyte growth factor stimulates motility, chemotaxis and mitogenesis in ovarian carcinoma cells expressing high levels of c-met. Int J Cancer 1997; 73: 151-155.
10. Taipale J, Keski-Oja J. Growth factors in the extracellular matrix. FASEB J 1997; 11: 51-59.
11. Tatsumi R, Allen RE. Active hepatocyte growth factor is present in skeletal muscle extracellular matrix. Muscle Nerve 2004; 30: 654-658.
12. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008; 7: 504-516.
13. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012; 487: 500-504.
14. Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012; 487: 505-509.
15. Ayhan A, Ertunc D, Tok EC, Ayhan A. Expression of the c-Met in advanced epithelial ovarian cancer and its prognostic significance. Int J Gynecol Cancer 2005; 15: 618-623.
16. Zillhardt M, Christensen JG, Lengyel E. An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis. Neoplasia 2010; 12: 1-10.
17. Zillhardt M, Park SM, Romero IL, Sawada K, Montag A, Krausz T et al. Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis. Clin Cancer Res 2011; 17: 4042-4051.
18. Gordon MS, Sweeney CS, Mendelson DS, Eckhardt SG, Anderson A, Beaupre DM et al. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors. Clin Cancer Res 2010; 16: 699-710.
19. Liu X, Newton RC, Scherle PA. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends Mol Med 2009; 16: 37-45.
20. Lyon M, Deakin JA, Mizuno K, Nakamura T, Gallagher JT. Interaction of hepatocyte growth factor with heparan sulfate. Elucidation of the major heparan sulfate structural determinants. J Biol Chem 1994; 269: 11216-11223.
21. Ashikari S, Habuchi H, Kimata K. Characterization of heparan sulfate oligosaccharides that bind to hepatocyte growth factor. J Biol Chem 1995; 270: 29586-29593.
22. Zioncheck TF, Richardson L, Liu J, Chang L, King KL, Bennett GL et al. Sulfated oligosaccharides promote hepatocyte growth factor association and govern its mitogenic activity. J Biol Chem 1995; 270: 16871-16878.
23. Flynn DL, Ahn YM, Berger MS, Caldwell T, Hood MM, Kaufman MD et al. Rebastinib and DCC-2701: targeting of resistance mechanisms in cancer treatment. ACS National Meeting, New Orleans, 8 April, MEDI 209 2013.
24. Sawada K, Radjabi AR, Shinomiya N, Kistner E, Kenny H, Becker AR et al. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res 2007; 67: 1670-1679.
25. Kwon Y, Cukierman E, Godwin AK. Differential expressions of adhesive molecules and proteases define mechanisms of ovarian tumor cell matrix penetration/invasion. PLoS One 2011; 6: e18872.
26. Furge KA, Zhang YW, Vande Woude GF. Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene 2000; 19: 5582-5589.
27. Pan BS, Chan GK, Chenard M, Chi A, Davis LJ, Deshmukh SV et al. MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res 2010; 70: 1524-1533.
28. Ponzetto C, Bardelli A, Zhen Z, Maina F, dalla Zonca P, Giordano S et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 1994; 77: 261-271.
29. Michieli P, Basilico C, Pennacchietti S, Maffe A, Tamagnone L, Giordano S et al. Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. Oncogene 1999; 18: 5221-5231.
30. Miyata Y, Kanetake H, Kanda S. Presence of phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor progression and survival in patients with conventional renal cell carcinoma. Clin Cancer Res 2006; 12: 4876-4881.
31. Marchand-Adam S, Marchal J, Cohen M, Soler P, Gerard B, Castier Y et al. Defect of hepatocyte growth factor secretion by fibroblasts in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003; 168: 1156-1161.
32. Matsuoka H, Sisson TH, Nishiuma T, Simon RH. Plasminogen-mediated activation and release of hepatocyte growth factor from extracellular matrix. Am J Respir Cell Mol Biol 2006; 35: 705-713.
33. Lyon M, Deakin JA, Rahmoune H, Fernig DG, Nakamura T, Gallagher JT. Hepatocyte growth factor/scatter factor binds with high affinity to dermatan sulfate. J Biol Chem 1998; 273: 271-278.
34. Nayeri F, Nayeri T, Aili D, Brudin L, Liedberg B. Clinical impact of real-time evaluation of the biological activity and degradation of hepatocyte growth factor. Growth Factors 2008; 26: 163-171.
35. Hamilton TC, Young RC, McKoy WM, Grotzinger KR, Green JA, Chu EW et al. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res 1983; 43: 5379-5389.
36. Langdon SP, Lawrie SS, Hay FG, Hawkes MM, McDonald A, Hayward IP et al. Characterization and properties of nine human ovarian adenocarcinoma cell lines. Cancer Res 1988; 48: 6166-6172.
37. Quiros RM, Valianou M, Kwon Y, Brown KM, Godwin AK, Cukierman E. Ovarian normal and tumor-associated fibroblasts retain in vivo stromal characteristics in a 3-D matrix-dependent manner. Gynecol Oncol 2008; 110: 99-109.
38. Amatangelo MD, Bassi DE, Klein-Szanto AJ, Cukierman E. Stroma-derived threedimensional matrices are necessary and sufficient to promote desmoplastic differentiation of normal fibroblasts. Am J Pathol 2005; 167: 475-488.
39. Beacham DA, Amatangelo MD, Cukierman E. Preparation of extracellular matrices produced by cultured and primary fibroblasts. Curr Protoc Cell Biol 2007 Chapter 10 Unit 10 9.
40. Castello-Cros R, Cukierman E. Stromagenesis during tumorigenesis: characterization of tumor-associated fibroblasts and stroma-derived 3D matrices. Methods Mol Biol 2009; 522: 275-305.
41. Cukierman E, Pankov R, Stevens DR, Yamada KM. Taking cell-matrix adhesions to the third dimension. Science 2001; 294: 1708-1712.